Workshop on Engineering Immune Cells for Cancer Therapy

Workshop on Engineering Immune Cells for Cancer Therapy

A Pre-Conference Program; additional registration fee applies 

CAR T treatments have led to improved outcomes for patients with hematologic malignancies. However, the same level of success has not been achieved in most solid tumors, and other immune cell types beyond T cells are also being explored preclinically and clinically. This workshop will therefore highlight the multitude of cellular therapy approaches being applied for the treatment of cancer, including many T cell strategies, alternative immune cells, practical considerations and novel technologies.

Monday, Nov. 9, 2020*

*Dates and times subject to change.  

Workshop Organizers

  • Christine Brown, PhD – City of Hope 
  • Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
  • Marco Ruella, MD – University of Pennsylvania 

Program Schedule*

*Program schedule subject to change.  

Introduction
Katayoun Rezvani, MD, PhD - The University of Texas MD Anderson Cancer Center
Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs 
Neoantigen-expanded T cells/TCRs
Steven A. Rosenberg, MD, PhD - National Cancer Institute, National Institutes of Health
TILs
John Haanen, MD, PhD - Netherlands Cancer Institute
Endogenous T cells
Cassian Yee, MD - The University of Texas MD Anderson Cancer Center
Session I Panel Discussion - Session I Speakers
Break
Session II: Novel Approaches to Enhance CAR T cell Therapy 
Next-generation CARS for blood cancers
Michael Hudecek, MD - University of Wuerzburg
CAR for solid tumors
Saul Priceman, PhD - City of Hope
Resistance and next-generation approaches
Marco Ruella, MD - University of Pennsylvania
Session II Panel Discussion - Session II Speakers
Lunch 
Session III: CAR-Based Strategies Beyond T Lymphocytes 
NK cells
Katayoun Rezvani, MD, PhD - The University of Texas MD Anderson Cancer Center
Macrophages
Michael Klichinsky, PharmD, PhD - Carisma Therapeutics
B cells
Justin Taylor, PhD - Fred Hutchinson Cancer Research Center
Session III Panel Discussion - Session III Speakers
Break
Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic 
Novel concepts in manufacturing
Isabelle Riviere, PhD - Memorial Sloan Kettering Cancer Center
Off-the-shelf, including allogeneic and iPSCs
Barbra J. Sasu, PhD - Allogene Therapeutics
Genetic engineering and novel approaches
Carl H. June, MD - University of Pennsylvania
Session IV Panel Discussion - Session IV Speakers

Target Audience

The target audience for this program includes basic scientists and clinical investigators from academic institutions, venture capital, industry, and regulatory agencies. Additional audiences benefiting from this program include clinicians, graduate students, and postdoctoral fellows involved in cancer research and its translation into clinical practice, as well as those involved in manufacturing of cellular therapies.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Explain the status and direction of cellular therapies for cancer treatment
  • Identify highly relevant challenges and questions facing the translation of cellular therapies from preclinical to clinical settings
  • Describe cellular therapies employing immune cells other than T cells
  • Summarize novel technologies that are enabling broader application of cellular therapies for cancer
This program is not eligible for continuing education credit.
Workshop_2019.jpg
workshop_2019_2.jpg